This product consists of a CRISPR/Cas9-edited polyclonal knockout cell population derived from Jurkat T lymphoblast cells, targeting the APIP gene. The APIP knockout model is generated through CRISPR/Cas9-mediated gene disruption, resulting in a heterogeneous population of cells with loss-of-function mutations. This polyclonal format allows researchers to study the functional consequences of APIP deficiency without clonal selection bias, providing a representative loss-of-function model for apoptosis and metabolic studies. The knockout cells are suitable for a range of biochemical and cell-based assays, including those examining apoptosome regulation and methionine salvage pathway activity.
The Jurkat cell line, established from the peripheral blood of a 14-year-old male with T cell leukemia, serves as a widely used model for T cell signaling and apoptosis. These suspension T lymphoblast cells exhibit characteristics of immature T cells and have been instrumental in dissecting T cell receptor signaling, apoptosis pathways, and mechanisms of leukemogenesis. Their well-defined apoptotic machinery and sensitivity to various death stimuli make them an ideal host for studying the intrinsic apoptosis pathway and its regulation by APIP.
APIP (APAF1-interacting protein) is a dual-function protein that directly binds to APAF1 and cytochrome c, preventing the formation of the apoptosome complex and subsequent activation of caspase-9 and caspase-3. Through this interaction, APIP acts as an inhibitor of intrinsic apoptosis, a pathway triggered by cellular stress signals and DNA damage. In addition to its anti-apoptotic role, APIP functions as a methylthioribulose-1-phosphate dehydratase in the methionine salvage pathway, catalyzing a key step that regenerates methionine and contributes to S-adenosylmethionine synthesis. Upstream regulators such as death receptor ligands and cellular stress signals can modulate APIP activity, and its loss disrupts both apoptotic regulation and methionine metabolism.
In Jurkat T cells, knockout of APIP profoundly sensitizes the cells to apoptotic stimuli, including death receptor ligands and DNA-damaging agents, by releasing the brake on apoptosome formation. This results in enhanced caspase-9 and caspase-3 activation, cytochrome c release, and cell death. Simultaneously, disruption of the methionine salvage pathway impairs methionine and S-adenosylmethionine levels, potentially affecting methylation reactions and proliferation. Thus, these APIP knockout Jurkat polyclonal cells provide a relevant model for investigating the interplay between apoptosis resistance and metabolic reprogramming in T cell leukemia and other cancers.
This knockout model is valuable for elucidating mechanisms of therapy resistance in T cell acute lymphoblastic leukemia and for screening drugs that target the apoptosome or methionine metabolism. Specific applications include performing caspase-3/7 activity assays, Annexin V flow cytometry, and cytochrome c release assays to quantify apoptosis. Additionally, these cells can be used for co-immunoprecipitation studies to confirm APIP?CAPAF1 interactions, western blotting for caspase cleavage, and metabolite profiling of the methionine salvage pathway. For further information, please contact Ascent Research.
